Interferon is also available for some of the carriers of mini-tertiary. However, it is recommended to use the drug under the guidance of a specialist. Interferon is a broad-spectrum antiviral drug that can also regulate the body’s immunity to achieve the effect of inhibiting the hepatitis B virus, and long-term use can control the virus and delay the development of the disease into cirrhosis and liver cancer. In addition, the new guidelines in 2019 propose the use of interferon treatment, which can achieve the effect of clinical cure, that is, to achieve the disappearance of hepatitis B surface antigen and the emergence of hepatitis B surface antibody, so hepatitis B carriers can also play interferon. Interferon therapy is more effective in hepatitis B minor triyang carriers who are young, female, with low viral replication and low hepatitis B surface antigen titer. It is recommended that hepatitis B minor triple Yang carriers go to the hospital to check hepatitis B 5, hepatitis B DNA, ultrasound and so on, to clarify whether interferon treatment can be carried out.